Literature DB >> 25065332

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity.

Sho-ichi Yamagishi1, Yuji Ishibashi2, Ayako Ojima2, Tatsushi Sugiura3, Takanori Matsui2.   

Abstract

Entities:  

Keywords:  Atherosclerosis; DPP-4 inhibitor; Inflammation; Linagliptin; Oxidative stress; Type 2 diabetes; Uric acid; Vascular complications; Vascular damage; Xanthine oxidase

Mesh：

Substances：

Year:  2014        PMID： 25065332     DOI： 10.1016/j.ijcard.2014.07.023

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  12 in total

Review 1.  More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.

Authors:  Shreyasi Gupta; Utpal Sen
Journal:  Pharmacol Res       Date:  2019-08-08       Impact factor: 7.658

2.  Possible vasculoprotective role of linagliptin against sodium arsenite-induced vascular endothelial dysfunction.

Authors:  Uma Jyoti; Sunil Kumar Kansal; Puneet Kumar; Sandeep Goyal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-02       Impact factor: 3.000

Review 3.  The clinical application of linagliptin in Asians.

Authors:  Chu-Qing Cao; Yu-Fei Xiang; Zhi-Guang Zhou
Journal:  Ther Clin Risk Manag       Date:  2015-09-16       Impact factor: 2.423

Review 4.  Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.

Authors:  Sho-ichi Yamagishi; Kei Fukami; Takanori Matsui
Journal:  Cardiovasc Diabetol       Date:  2015-01-13       Impact factor: 9.951

5.  Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients.

Authors:  Yuki Fujimura; Yohei Yamauchi; Takayo Murase; Takashi Nakamura; Shu-Ichi Fujita; Tomohiro Fujisaka; Takahide Ito; Koichi Sohmiya; Masaaki Hoshiga; Nobukazu Ishizaka
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

Review 6.  The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.

Authors:  Keizo Kanasaki
Journal:  Clin Sci (Lond)       Date:  2018-02-28       Impact factor: 6.124

7.  Serum Uric Acid as an Independent Risk Factor for the Presence and Severity of Early-Onset Coronary Artery Disease: A Case-Control Study.

Authors:  Ting-Ting Tian; Hui Li; Sheng-Jie Chen; Qing Wang; Qing-Wu Tian; Bei-Bei Zhang; Jie Zhu; Guo-Wei He; Li-Min Lun; Chao Xuan
Journal:  Dis Markers       Date:  2018-10-23       Impact factor: 3.434

8.  The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose.

Authors:  Salheen M Salheen; Usha Panchapakesan; Carol A Pollock; Owen L Woodman
Journal:  PLoS One       Date:  2015-11-30       Impact factor: 3.240

9.  Teneligliptin Decreases Uric Acid Levels by Reducing Xanthine Dehydrogenase Expression in White Adipose Tissue of Male Wistar Rats.

Authors:  Chihiro Moriya; Hiroaki Satoh
Journal:  J Diabetes Res       Date:  2016-08-29       Impact factor: 4.011

10.  Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study.

Authors:  Hidetaka Hamasaki; Yasuteru Hamasaki
Journal:  World J Diabetes       Date:  2018-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.